US ruling favours Warner Chilcott on Sarafem patent
This article was originally published in Clinica
Shares of Warner Chilcott (formerly Galen Holdings) jumped by more than 5% after the company announced that it had won a dispute with Teva Pharmaceutical Industries about the infringement of a US patent for Sarafem (fluoxetine). Sarafem is indicated only for the treatment of pre-menstrual dysphoric disorder (PMDD).
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.